Phase 2 N=9 Treatment of Oral Premalignant Lesions With 5-ALA PDT
Leukoplakia · Erythroplakia
Primary: Maximum Tolerated Dose — 8 J/cm2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=21 Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
Head and Neck Cancer · Oral Leukoplakia
Primary: Patients' Overall Response — 0; 15; 2; 4 Participants
Phase 2 N=132 Bowman-Birk Inhibitor Concentrate in Preventing Cancer in Patients With Oral Leukoplakia
Lip and Oral Cavity Cancer · Oral Leukoplakia · Oropharyngeal Cancer
Primary: Relative Percent Change in Total Lesion Area After 6 Months on Study — -20.6; -17.1 percentage change
Phase 2 N=33 Safety and Efficacy of Nivolumab in Treating Oral Proliferative Verrucous Leukoplakia
Leukoplakia, Oral
Primary: Best Overall Response Rate (BORR) — 36.4 percentage of participants
Phase 2 N=21 Pimecrolimus Cream for Oral Lichen Planus
Oral Lichen Planus
Primary: The Primary Efficacy Variable Was the Change in the Investigator's Global Assessment of the Overall Severity of Disease From Baseline to Week 6. — 2.4; 2.45; 1.6; 2.27…
N/A N=27 Comparison or Rose Bengal and Toluidine Blue Staining for Lesion Detection Efficacy
Oral Leukoplakia · Oral Lichen Planus · Premalignant Lesion
Primary: Number and Percentage of Lesions That Were Stained Positive — 29; 28 lesions — p=0.005
Phase 3 N=928 Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity
Squamous Cell Carcinoma of the Oral Cavity · Squamous Cell Carcinoma of the Soft Palate
Primary: Overall Survival (OS) — 46.3; 58.1; 52.9 months — p=0.4051
Phase 1 N=100 Oral Mucosal Effects In Adult Smokers Associated With Two Nicotine Lozenge Formulations
Safety Issues
Primary: OMI-20 Total Score Change From Baseline to Day 3 — 0.0; 0.0 score on a scale
Phase 2 N=59 Treatment of Oral Warts in HIV+ Patients
Papillomatosis · HIV Infections
Primary: Change in Total Oral Mucosal Area Covered by Warts. — 11; 2 participants — p=0.30
Phase 2 N=41 Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention
Squamous Cell Carcinoma of Mouth · Intraepithelial Neoplasia
Primary: Light Microscopic Histologically Scored Diagnoses Pretreatment to Post Treatment — 2.36; 2.83; 1.9; 2.58 unit on histologic grade scale — p=0.048
N/A N=78 Salivary and Serum Leptin Levels in Oral Lichen Planus Patients: A Case-control Study.
Oral Lichen Planus · Leptin Levels
Primary: Serum Leptin Level — 13.23; 4.20 ng/ml
N/A N=93 Methylation of p16 CpG Island And Malignant Transformation of Oral Epithelial Dysplasia
Oral Epithelial Dysplasia, Mild or Moderate Grade
Primary: The Number of Participants With Both Clinical and Histological Evidence of Malignant Transformation of Oral Epithelial Dysplasia — 32; 46 participants
Phase 2 N=15 Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia
Oral Cavity Carcinoma · Oral Intraepithelial Neoplasia
Primary: Oral Cancer-free Survival — NA; 6.7 Months
N/A N=100 Leukocyte Function in Chronic Obstructive Pulmonary Disease (COPD)
COPD · Emphysema · Chronic Bronchitis
Primary: Effective Concentration (EC 50) of GRO Alpha — 1.5; 0.9; 0.6 ng/ml — p=0.05
N/A N=17 Cytokines in Papillon-Lefèvre Syndrome
Papillon-Lefevre Disease
Primary: Serum Concentrations of Interleukin (IL)-1 Beta — 1100.00; 896.21; 65559; 45734 pg/ml
Phase 4 N=20 Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis
Actinic Cheilitis
Primary: Number of Participants With a Change in Clearance From Baseline — 1; 1; 9; 4 Participants
Phase 4 N=49 Compare Anti-inflammatory Dentifrices
Gingivitis
Primary: Gingival Index (GI) — 1.04; 1.01 units on a scale — p=<0.05
N/A N=38 Fluoride Varnish for Treatment of White Spot Lesions
White Spot Lesions
Primary: DIAGNOdent Readings at Baseline, Three and Six Months - Intergroup Comparison — 5.10; 6.01; 4.08; 5.50 units on a scale — p=0.636
N/A N=281 Oral Cell DNA Adducts in Smokers
Lung Cancer
Primary: Concentration of γ-OH-Acr-dGuo, a Major Acrolein-DNA Adduct — 49.7; 67.1; 46.5 10^9 nucleotides/mL